Drug Information

Drug General Information
Drug ID
D0D4CX
Former ID
DIB012229
Drug Name
Pegamotecan
Synonyms
Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
Drug Type
Small molecular drug
Indication Esophageal cancer [ICD9: 150; ICD10:C15] Phase 2 [521591]
Company
Enzon Pharmaceuticals Inc
Structure
Download
2D MOL

3D MOL
Formula
C53H50N6O13
Canonical SMILES
[C@@]1(C(=O)OCc2c1cc1n(c2=O)Cc2c1nc1c(c2)cccc1)(OC(=O)[<br />C@@H](NC(=O)COCCOCC(=O)N[C@H](C(=O)O[C@@]1(C(=O)OCc2c1c<br />c1n(c2=O)Cc2c1nc1c(c2)cccc1)CC)C)C)CC
PubChem Compound ID
70689326
Target and Pathway
Target(s) Toposisomerase-1 Target Info Inhibitor [529412]
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway DNA replication
Pathway Interaction Database Caspase Cascade in Apoptosis
WikiPathways Integrated Pancreatic Cancer Pathway
References
Ref 521591ClinicalTrials.gov (NCT00080002) Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health.
Ref 529412A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.